^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    177Lu-LNC1004

    i
    Other names: 177Lu-LNC1004, 177Lu-EB-FAPI
    Associations

    News

    Trials
    Company:
    Dongcheng Pharma
    Drug class:
    Ionizing radiation emitter, FAP inhibitor
    Related drugs:
    Associations

    News

    Trials
    21d
    INDIGO-FAPI: Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Institut Curie
    New P2 trial
    |
    177Lu-LNC1004
    6ms
    Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. (PubMed, Signal Transduct Target Ther)
    This was emphasized by the observed increase in antigen processing and presentation juxtaposed with T cell inactivation. In conclusion, our data supported the efficacy of immunotherapy combined with 177Lu-LNC1004 for cancer patients with FAP-positive tumors.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    CD8 (cluster of differentiation 8) • FAP (Fibroblast activation protein, alpha)
    |
    177Lu-LNC1004
    1year
    CISPD-5: A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors (clinicaltrials.gov)
    P1, N=29, Recruiting, Zhejiang University
    New P1 trial • Metastases
    |
    177Lu-LNC1004
    almost2years
    The Safety and Dosimetry Study of 177Lu-LNC1004 Injection (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Yantai LNC Biotechnology Singapore PTE. LTD.
    New P1 trial
    |
    FAP (Fibroblast activation protein, alpha)
    |
    177Lu-LNC1004